

HLAVNÍ TÉMA

NOVÉ VZNIKLY REFRAKTERNÍ STATUS EPILEPTICUS

8. Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. *Epilepsia*. 2018;59(4):739-744. doi: 10.1111/epi.14016.
9. Hirsch LJ, Gaspard N. Status epilepticus. *Continuum (Minneapolis Minn)*. 2013;19(3 Epilepsy):767-94. doi: 10.1212/01.CON.0000431395.16229.5a.
10. Iizuka T, Kanazawa N, et al. Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy. *Neurology Neuroimmunol Neuroinflamm*. 2017;4(6):e396. doi: 10.1212/NXI.0000000000000396.
11. Kessi M, Liu F, Zhan Y, et al. Efficacy of different treatment modalities for acute and chronic phases of the febrile infection-related epilepsy syndrome: A systematic review. *Seizure*. 2020;79:61-68. doi: 10.1016/j.seizure.2020.04.015.
12. Körtvelyessy P, Lerche H, Weber Y. FIRES and NORSE are distinct entities. *Epilepsia*. 2012;53(7):1276. doi: 10.1111/j.1528-1167.2012.03517.x.
13. Kramer U, Chi CS, Lin KL, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. *Epilepsia*. 2011;52(11):1956-65. doi: 10.1111/j.1528-1167.2011.03250.x.
14. Luo T, Wang Y, Lu G, et al. Vagus nerve stimulation for super-refractory status epilepticus in febrile infection-related epilepsy syndrome: a pediatric case report and literature review. *Childs Nerv Syst*. 2022 Jul;38(7):1401-1404. doi: 10.1007/s00381-021-05410-6.
15. Meletti S, Slonkova J, Mareckova I, et al. Claustrium damage and refractory status epilepticus following febrile illness. *Neurology*. 2015;85(14):1224-32. doi: 10.1212/WNL.0000000000001996.
16. Meletti S, Giovannini G, d'Orsi G, et al. New-Onset Refractory Status Epilepticus with Claustrium Damage: Definition of the Clinical and Neuroimaging Features. *Front Neurol*. 2017;8:111. doi: 10.3389/fneur.2017.00111.
17. Mikaeloff Y, Jambaqué I, Hertz-Pannier L, et al. Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis. *Epilepsy Res*. 2006;69(1):67-79. doi: 10.1016/j.eplepsyres.2006.01.002.
18. Nababout R, Vezzani A, Dulac O, Chiron C. Acute encephalopathy with inflammation-mediated status epilepticus. *Lancet Neurol*. 2011;10(1):99-108. doi: 10.1016/S1474-4422(10)70214-3.
19. Nababout R. FIRES and IHHE: Delineation of the syndromes. *Epilepsia*. 2013;54(Suppl. 6):54-6. doi: 10.1111/epi.12278.
20. Sakuma H, Tanuma N, Kuki I, et al. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus. *J Neurol Neurosurg Psychiatry*. 2015;86(7):820-2. doi: 10.1136/jnnp-2014-309388.
21. Sato Y, Numata-Uematsu Y, Uematsu M, et al. Acute encephalitis with refractory, repetitive partial seizures: Pathological findings and a new therapeutic approach using tacrolimus. *Brain Dev*. 2016;38(8):772-6. doi: 10.1016/j.braindev.2016.02.006.
22. Sculier C, Gaspard N. New onset refractory status epilepticus (NORSE). *Seizure*. 2019;68:72-78. doi: 10.1016/j.seizure.2018.09.018.
23. Sutter R, Marsch S, Fuhr P, et al. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. *Neurology*. 2014;82(8):656-64. doi: 10.1212/WNL.0000000000000009.
24. Thakur KT, Probasco JC, Hocker SE, et al. Ketogenic diet for adults in super-refractory status epilepticus. *Neurology*. 2014;82(8):665-70. doi: 10.1212/WNL.0000000000000151.
25. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol*. 2013;12(2):157-65. doi: 10.1016/S1474-4422(12)70310-1.
26. Trinka E, Leitinger M. Management of Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus. *Continuum (Minneapolis Minn)*. 2022;28(2):559-602. doi: 10.1212/CON.0000000000001103.
27. van Baalen A, Vezzani A, Häusler M, et al. Febrile Infection-Related Epilepsy Syndrome: Clinical Review and Hypotheses of Epileptogenesis. *Neuropediatrics*. 2017;48(1):5-18. doi: 10.1055/s-0036-1597271.
28. Wickstrom R, Taraschenko O, Dilella R, et al. International NORSE Consensus Group. International consensus recommendations for management of New Onset Refractory Status Epilepticus (NORSE) incl. Febrile Infection-Related Epilepsy Syndrome (FIRES): Statements and Supporting Evidence. *Epilepsia*. 2022;63(11):2840-64. doi: 10.1111/epi.17397.
29. Wilder-Smith EP, Lim EC, Teoh HL, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. *Ann Acad Med Singap*. 2005;34(7):417-20.
30. Yamazoe T, Okanishi T, Yamamoto A, et al. New-onset refractory status epilepticus treated with vagus nerve stimulation: A case report. *Seizure*. 2017;47:1-4. doi: 10.1016/j.seizure.2017.02.011.

ON-LINE KURZ

On-line kurz pro praktické neurology 2023

PŘEDNÁŠKY

- **Indukční léčba RS, včasné nasazení vysoce účinné terapie**
MUDr. Marta Vachová
- **Co se děje při imunorekonstituci – nové detailní poznatky**
MUDr. Veronika Tichá, Ph.D.
- **MR v prognóze a monitoraci aktivity u RS pacientů**
prof. MUDr. Manuela Vaněčková, Ph.D.
- **Kdy je čas na imunorekonstituční léčbu?** – MUDr. Marta Vachová
- **TOS – anatomie, klinika, diferenciální diagnostika** – MUDr. Tomáš Bauer
- **TOS – klinické vyšetření, EMG, konzervativní léčba**
MUDr. Štěpánka Brušáková, MBA

ODBORNÝ GARANT: MUDr. Marta Vachová

POŘADATEL: SOLEN, s. r. o.,
ve spolupráci s Neurologickým oddělením
s RS centrem, Nemocnice Teplice, o. z. –
Krajská zdravotní, a. s., Teplice.

POČET
KREDITŮ **2**

Registrace
ZDARMA

TERMÍN
prosinec 2023
až listopad 2024
dostupný na
online.solen.cz

ZLATÝ
PARTNER

MERCK

